Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

The Complex Landscape of PTEN mRNA Regulation.

Sellars E, Gabra M, Salmena L.

Cold Spring Harb Perspect Med. 2019 Dec 23. pii: a036236. doi: 10.1101/cshperspect.a036236. [Epub ahead of print]

PMID:
31871240
2.

Investigating the duality of Inpp4b function in the cellular transformation of mouse fibroblasts.

Mangialardi EM, Chen K, Salmon B, Vacher J, Salmena L.

Oncotarget. 2019 Oct 29;10(59):6378-6390. doi: 10.18632/oncotarget.27293. eCollection 2019 Oct 29.

3.

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.

4.

Serum osteoprotegerin levels and mammographic density among high-risk women.

Moran O, Zaman T, Eisen A, Demsky R, Blackmore K, Knight JA, Elser C, Ginsburg O, Zbuk K, Yaffe M, Narod SA, Salmena L, Kotsopoulos J.

Cancer Causes Control. 2018 Jun;29(6):507-517. doi: 10.1007/s10552-018-1035-y. Epub 2018 Apr 20.

PMID:
29679262
5.

SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.

Dzneladze I, Woolley JF, Rossell C, Han Y, Rashid A, Jain M, Reimand J, Minden MD, Salmena L.

PLoS One. 2018 Feb 7;13(2):e0191510. doi: 10.1371/journal.pone.0191510. eCollection 2018. Erratum in: PLoS One. 2018 Mar 29;13(3):e0195417.

6.

microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.

Gabra MM, Salmena L.

Front Oncol. 2017 Oct 30;7:255. doi: 10.3389/fonc.2017.00255. eCollection 2017. Review.

7.

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.

8.

Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.

Chehade R, Pettapiece-Phillips R, Salmena L, Kotlyar M, Jurisica I, Narod SA, Akbari MR, Kotsopoulos J.

Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8.

9.

Preface.

Salmena L, Stambolic V.

Methods Mol Biol. 2016;1388:v. No abstract available.

PMID:
27482589
10.

Measurement of PTEN by Flow Cytometry.

Woolley JF, Salmena L.

Methods Mol Biol. 2016;1388:39-51. doi: 10.1007/978-1-4939-3299-3_4.

PMID:
27033069
11.

PTEN: History of a Tumor Suppressor.

Salmena L.

Methods Mol Biol. 2016;1388:3-11. doi: 10.1007/978-1-4939-3299-3_1.

PMID:
27033066
12.

Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.

Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, Kotsopoulos J.

Cancer Prev Res (Phila). 2016 Jan;9(1):83-8. doi: 10.1158/1940-6207.CAPR-15-0291. Epub 2015 Nov 2.

13.

Targeting mitochondrial RNA polymerase in acute myeloid leukemia.

Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, Andreazza AC, Psarianos P, Schimmer AD, Salmena L, Laposa RR.

Oncotarget. 2015 Nov 10;6(35):37216-28. doi: 10.18632/oncotarget.6129.

14.

Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.

Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J.

Eur J Gynaecol Oncol. 2015;36(3):260-7.

PMID:
26189250
15.

Phosphoinositide signaling in cancer: INPP4B Akt(s) out.

Woolley JF, Dzneladze I, Salmena L.

Trends Mol Med. 2015 Sep;21(9):530-2. doi: 10.1016/j.molmed.2015.06.006. Epub 2015 Jul 3.

PMID:
26150301
16.

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP.

Cancer Discov. 2015 Jul;5(7):740-51. doi: 10.1158/2159-8290.CD-14-1347. Epub 2015 Apr 16.

17.

INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.

Dzneladze I, He R, Woolley JF, Son MH, Sharobim MH, Greenberg SA, Gabra M, Langlois C, Rashid A, Hakem A, Ibrahimova N, Arruda A, Löwenberg B, Valk PJ, Minden MD, Salmena L.

Leukemia. 2015 Jul;29(7):1485-95. doi: 10.1038/leu.2015.51. Epub 2015 Mar 4.

PMID:
25736236
18.

BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.

Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA.

Br J Cancer. 2014 Sep 23;111(7):1269-74. doi: 10.1038/bjc.2014.391. Epub 2014 Jul 15.

19.

Pseudogene redux with new biological significance.

Salmena L.

Methods Mol Biol. 2014;1167:3-13. doi: 10.1007/978-1-4939-0835-6_1. Review.

PMID:
24823767
20.

Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function.

Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, Lunardi A, Webster K, Ng C, Newton RH, Knoblauch N, Guarnerio J, Ito K, Turka LA, Beck AH, Pinton P, Bronson RT, Wei W, Pandolfi PP.

Cell. 2014 Apr 24;157(3):595-610. doi: 10.1016/j.cell.2014.03.027.

21.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

22.

From photomorphogenesis to cancer: a CSN journey.

Salmena L, Hakem R.

Cell Cycle. 2013 Jan 15;12(2):205-6. doi: 10.4161/cc.23422. Epub 2012 Jan 15. No abstract available.

23.

The functions and regulation of the PTEN tumour suppressor.

Song MS, Salmena L, Pandolfi PP.

Nat Rev Mol Cell Biol. 2012 Apr 4;13(5):283-96. doi: 10.1038/nrm3330. Review.

PMID:
22473468
24.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res. 2012 Mar 9;14(2):R42.

25.

BRCA1 haploinsufficiency: consequences for breast cancer.

Salmena L, Narod S.

Womens Health (Lond). 2012 Mar;8(2):127-9. doi: 10.2217/whe.12.2.

PMID:
22375716
26.

BRCA1 and BRCA2 mutations and breast cancer.

Narod SA, Salmena L.

Discov Med. 2011 Nov;12(66):445-53.

27.

Role of Pirh2 in mediating the regulation of p53 and c-Myc.

Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, Madore J, Boutros P, Sheng Y, Chesi M, Bergsagel PL, Perez-Ordonez B, Mes-Masson AM, Penn L, Squire J, Chen X, Jurisica I, Arrowsmith C, Sanchez O, Benchimol S, Hakem R.

PLoS Genet. 2011 Nov;7(11):e1002360. doi: 10.1371/journal.pgen.1002360. Epub 2011 Nov 17.

28.

Caspase-8 inactivation in T cells increases necroptosis and suppresses autoimmunity in Bim-/- mice.

Bohgaki T, Mozo J, Salmena L, Matysiak-Zablocki E, Bohgaki M, Sanchez O, Strasser A, Hakem A, Hakem R.

J Cell Biol. 2011 Oct 17;195(2):277-91. doi: 10.1083/jcb.201103053.

29.

Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP.

Cell. 2011 Oct 14;147(2):344-57. doi: 10.1016/j.cell.2011.09.029.

30.

Neuronal deletion of caspase 8 protects against brain injury in mouse models of controlled cortical impact and kainic acid-induced excitotoxicity.

Krajewska M, You Z, Rong J, Kress C, Huang X, Yang J, Kyoda T, Leyva R, Banares S, Hu Y, Sze CH, Whalen MJ, Salmena L, Hakem R, Head BP, Reed JC, Krajewski S.

PLoS One. 2011;6(9):e24341. doi: 10.1371/journal.pone.0024341. Epub 2011 Sep 16.

31.

A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP.

Cell. 2011 Aug 5;146(3):353-8. doi: 10.1016/j.cell.2011.07.014. Epub 2011 Jul 28.

32.

A Role for PML in Innate Immunity.

Lunardi A, Gaboli M, Giorgio M, Rivi R, Bygrave A, Antoniou M, Drabek D, Dzierzak E, Fagioli M, Salmena L, Botto M, Cordon-Cardo C, Luzzatto L, Pelicci PG, Grosveld F, Pandolfi PP.

Genes Cancer. 2011 Jan;2(1):10-9. doi: 10.1177/1947601911402682.

33.

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.

Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP.

Cell. 2011 Jan 21;144(2):187-99. doi: 10.1016/j.cell.2010.12.020.

34.

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.

Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP.

Nature. 2010 Jun 24;465(7301):1033-8. doi: 10.1038/nature09144.

35.

Faithfull modeling of PTEN loss driven diseases in the mouse.

Nardella C, Carracedo A, Salmena L, Pandolfi PP.

Curr Top Microbiol Immunol. 2010;347:135-68. doi: 10.1007/82_2010_62. Review.

PMID:
20549475
36.

Subtle variations in Pten dose determine cancer susceptibility.

Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP.

Nat Genet. 2010 May;42(5):454-8. doi: 10.1038/ng.556. Epub 2010 Apr 18.

37.

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.

Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP.

Sci Signal. 2010 Apr 13;3(117):ra29. doi: 10.1126/scisignal.2000594. Erratum in: Sci Signal. 2010;3(123):er6.

38.

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC.

Cancer Cell. 2009 Aug 4;16(2):115-25. doi: 10.1016/j.ccr.2009.06.006.

39.

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT.

Blood. 2009 Jul 16;114(3):647-50. doi: 10.1182/blood-2009-02-206722. Epub 2009 May 20.

40.

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP.

J Clin Invest. 2008 Sep;118(9):3065-74. doi: 10.1172/JCI34739.

41.

The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.

Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, Pandolfi PP.

Nature. 2008 Oct 9;455(7214):813-7. doi: 10.1038/nature07290. Epub 2008 Aug 20.

42.

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.

Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP.

Genes Dev. 2008 Aug 15;22(16):2172-7. doi: 10.1101/gad.1699608.

43.

SnapShot: PTEN signaling pathways.

Carracedo A, Salmena L, Pandolfi PP.

Cell. 2008 May 2;133(3):550.e1. doi: 10.1016/j.cell.2008.04.023. No abstract available.

44.

Tenets of PTEN tumor suppression.

Salmena L, Carracedo A, Pandolfi PP.

Cell. 2008 May 2;133(3):403-14. doi: 10.1016/j.cell.2008.04.013.

45.

Distinct in vivo roles of caspase-8 in beta-cells in physiological and diabetes models.

Liadis N, Salmena L, Kwan E, Tajmir P, Schroer SA, Radziszewska A, Li X, Sheu L, Eweida M, Xu S, Gaisano HY, Hakem R, Woo M.

Diabetes. 2007 Sep;56(9):2302-11. Epub 2007 Jun 11.

46.

Changing venues for tumour suppression: balancing destruction and localization by monoubiquitylation.

Salmena L, Pandolfi PP.

Nat Rev Cancer. 2007 Jun;7(6):409-13. doi: 10.1038/nrc2145. Epub 2007 May 17. Review.

PMID:
17508027
47.

Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling.

Lemmers B, Salmena L, Bidère N, Su H, Matysiak-Zablocki E, Murakami K, Ohashi PS, Jurisicova A, Lenardo M, Hakem R, Hakem A.

J Biol Chem. 2007 Mar 9;282(10):7416-23. Epub 2007 Jan 9.

48.

Apoptosis caused by p53-induced protein with death domain (PIDD) depends on the death adapter protein RAIDD.

Berube C, Boucher LM, Ma W, Wakeham A, Salmena L, Hakem R, Yeh WC, Mak TW, Benchimol S.

Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14314-20. Epub 2005 Sep 23.

49.

Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder.

Salmena L, Hakem R.

J Exp Med. 2005 Sep 19;202(6):727-32. Epub 2005 Sep 12.

50.

Cellular FLICE-inhibitory protein is required for T cell survival and cycling.

Chau H, Wong V, Chen NJ, Huang HL, Lin WJ, Mirtsos C, Elford AR, Bonnard M, Wakeham A, You-Ten AI, Lemmers B, Salmena L, Pellegrini M, Hakem R, Mak TW, Ohashi P, Yeh WC.

J Exp Med. 2005 Aug 1;202(3):405-13. Epub 2005 Jul 25.

Supplemental Content

Loading ...
Support Center